MAPT and Alzheimer disease: The hypothetical cascade of AD biomarker changes has been proposed to follow a specific temporal ordering from amyloid deposition to tau aggregation, then to brain metabolic and structural changes, and finally to cognitive symptoms (Jack et al., 2013).